Soleno Therapeutics Inc
SLNO
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.76B
Close$
$81.46
53.7% upside
Current Fair Value
53.7% upsideUndervalued by 53.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.76 Billion |
|---|---|
| Enterprise Value | $2.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.41 |
| Beta | -2.22 |
| Outstanding Shares | 52,091,047 |
Return
| Return on Equity | 19.37% |
|---|---|
| Return on Assets | 15.79% |
| Return on Invested Capital | 18.18% |
Valuation & Multiples
| P/E Ratio | 28.75 |
|---|---|
| PEG | -16.75 |
| Price to Sales | 10.6 |
| Price to Book Ratio | 5.89 |
| Enterprise Value to Revenue | 9.24 |
| Enterprise Value to EBIT | 26.33 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.66
Average shareholder expectationRevenue Estimate
$93.77 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.91
Average shareholder expectationRevenue Estimate
$111.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.8546▲ 138.40% |
|---|---|
| Total Calls | 1,327,900▼ 43.96% |
| Total Puts | 2,462,700▲ 120.87% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 117.00%▼ 4.73% |
|---|---|
| Total Invested | $2.08B▼ 30.79% |
| Investors Holding | 236▼ 41.00% |
ESG Score
No data
About Soleno Therapeutics Inc
CEO: Anish Bhatnagar